Details

Autor(en) / Beteiligte

• Sychev, Dmitry A
• Zastrozhin, Mikhail S
• Miroshnichenko, Igor I
• Baymeeva, Natalia V
• Smirnov, Valery V
• Grishina, Elena A
• Ryzhikova, Kristina A
• Mirzaev, Karin B
• Markov, Dmitry D
• Skryabin, Valentin Y
• Snalina, Nataliya E
• Nosikova, Polina G
• Savchenko, Ludmila M
• Bryun, Evgeny A

Titel

Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration

Ist Teil von

• Drug metabolism and personalized therapy, 2017-09, Vol.32 (3), p.129

Ort / Verlag

Germany

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Haloperidol is used for the treatment of alcohol use disorders in patients with signs of alcohol-related psychosis. Haloperidol therapy poses a high risk of adverse drug reactions (ADR). Contradictory data, which include the effects of genetic polymorphisms in genes encoding the elements of haloperidol biotransformation system on haloperidol metabolism rate and plasma drug concentration ratio, are described in patients with different genotypes. The primary objective of this study was to investigate the effects of CYP2D6 and CYP3A5 genetic polymorphisms on haloperidol equilibrium concentration in patients with alcohol use disorder. The study included 69 male patients with alcohol use disorder. Genotyping was performed using the allele-specific real-time PCR. CYP2D6 and CYP3A were phenotyped with HPLC-MS using the concentration of endogenous substrate of the enzyme and its urinary metabolites [6-hydroxy-1,2,3,4-tetrahydro-β-carboline(6-HO-THBC) to pinoline ratio for CYP2D6 and 6-β-hydroxycortisol to cortisol ratio for CYP3A]. The equilibrium plasma concentration was determined using LC-MS-MS. Results indicated that both C/D indexes and equilibrium concentration levels depend on CYP2D6 genetic polymorphism, but only in patients receiving haloperidol intramuscular injections [0.26 (0.09; 0.48) vs. 0.54 (0.44; 0.74), p=0.037]. The study demonstrates that CYP2D6 genetic polymorphism (1846G>A) can affect haloperidol concentration levels in patients with alcohol use disorder.